Theralase Technologies Pioneers Light-Activated Cancer Therapies

2 min read | September 25, 2024 07:46 AM PDT | By Team Kalkine Media

Theralase Technologies Pioneers Light-Activated Cancer Therapies — Image source: shutterstock

Highlights

Successful Fundraising: Theralase Technologies has raised $544,000 through a non-brokered private placement, which will support its clinical trials and research initiatives.

Promising Drug Developments: The company’s lead drug formulation, Rudivar, has demonstrated superior effectiveness against Herpes Simplex Virus 1 (HSV-1) compared to the standard treatment Acyclovir.

Focus on Clinical Trials: Theralase is actively conducting a Phase II clinical trial for non-muscle invasive bladder cancer, alongside preclinical research on its innovative compound, Rutherrin.

Article

Theralase Technologies Inc., (OTC:TLTFF) a clinical-stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (PDCs), is making significant strides in both cancer treatment and antiviral therapies. Recently, the company completed a non-brokered private placement, successfully issuing 2.72 million units at $0.20 per unit, raising a total of $544,000. The proceeds from this placement are earmarked for the ongoing Phase II clinical trial targeting non-muscle invasive bladder cancer, further research on the compound Rutherrin, and other general corporate activities.

In addition to its work in oncology, Theralase is gaining attention for its lead drug formulation, Rudivar. Recent preclinical studies conducted at the University of Manitoba have shown that Rudivar is significantly more effective than Acyclovir in combating HSV-1, the virus responsible for herpes. Unlike Acyclovir, which only alleviates symptoms, Rudivar has demonstrated the ability to prevent viral replication by a remarkable 10 million-fold when administered shortly after infection. This positions Rudivar as a promising candidate in the global antiviral market, projected to reach around $71 billion by 2032, especially considering that approximately 3.7 billion people under the age of 50 are infected with HSV-1.

CEO Roger Dumoulin-White emphasized the importance of these advancements, noting that Rutherrin is showing promise in overcoming chemoresistance when used in conjunction with the chemotherapy drug Cisplatin. As Theralase continues to push forward with its innovative therapies, the company aims to make a significant impact in the treatment of both cancer and viral infections.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.